- User Profile
- Watchlists
- Bio Tech Plays. Mispricing
Bio Tech Plays. Mispricing
15+ years as a clinical vet, researcher & founder. I track biotech mispricings for analytical insights.
Watching
17
| Company | Price & Valuation | FV & Narrative | Valuation | Growth | Analyst Target | |
|---|---|---|---|---|---|---|
A176750 DuChemBIOLtd ₩7,310.0026.9% undervalued intrinsic discount 21.4%7D -19.1%3M | ||||||
BBIO BridgeBio Pharma US$84.02236.1% overvalued intrinsic discount 3.2%7D 14.7%3M | ||||||
AMGN Amgen US$376.044.5% overvalued intrinsic discount 2.7%7D 9.1%3M | ||||||
ROIV Roivant Sciences US$35.01250.1% overvalued intrinsic discount 1.4%7D 27.7%3M | ||||||
CAPR Capricor Therapeutics US$19.7066.0% undervalued intrinsic discount 1.3%7D -44.1%3M | ||||||
A214150 CLASSYS ₩44,450.0031.6% undervalued intrinsic discount 0.8%7D -25.2%3M | ||||||
FBIO Fortress Biotech US$3.3451.1% undervalued intrinsic discount -0.6%7D 43.3%3M | ||||||
ZTS Zoetis US$75.3513.2% undervalued intrinsic discount -1.6%7D -35.5%3M | ||||||
PRTC PureTech Health UK£1.2362.8% undervalued intrinsic discount -1.6%7D 0.3%3M | ||||||
INMD InMode US$15.1730.1% undervalued intrinsic discount -1.9%7D 5.3%3M | ||||||
A053030 BINEX ₩6,600.0070.8% undervalued intrinsic discount -2.1%7D -43.0%3M | ||||||
TDOC Teladoc Health US$8.7741.5% undervalued intrinsic discount -7.0%7D 52.5%3M | ||||||
RCKT Rocket Pharmaceuticals US$3.1968.1% undervalued intrinsic discount -7.3%7D -9.4%3M | ||||||
RARE Ultragenyx Pharmaceutical US$26.903.5% overvalued intrinsic discount -8.1%7D 11.6%3M | ||||||
AKBA Akebia Therapeutics US$1.2298.4% undervalued intrinsic discount -9.0%7D -14.7%3M | ||||||
MBIO Mustang Bio US$0.5668.8% undervalued intrinsic discount -10.5%7D -25.5%3M | ||||||
ZVRA Zevra Therapeutics US$9.5336.5% undervalued intrinsic discount -25.4%7D -5.5%3M |
Watching
17
| Company | Price & Valuation | FV & Narrative | Valuation | Growth | Analyst Target | |
|---|---|---|---|---|---|---|
A176750 DuChemBIOLtd 21.4%7D -19.1%3M | ₩7,310.00 26.9% undervalued intrinsic discount | PE 29.7x | S n/a | n/a | ||
BBIO BridgeBio Pharma 3.2%7D 14.7%3M | US$84.02 236.1% overvalued intrinsic discount | PS 28.4x | E 65.5% | US$105.26 | ||
AMGN Amgen 2.7%7D 9.1%3M | US$376.04 4.5% overvalued intrinsic discount | PE 26x | E 7.6% | US$356.69 | ||
ROIV Roivant Sciences 1.4%7D 27.7%3M | US$35.01 250.1% overvalued intrinsic discount | PB 5.6x | E 52.9% | US$38.35 | ||
CAPR Capricor Therapeutics 1.3%7D -44.1%3M | US$19.70 66.0% undervalued intrinsic discount | PB 4.1x | E 64.2% | US$53.60 | ||
A214150 CLASSYS 0.8%7D -25.2%3M | ₩44,450.00 31.6% undervalued intrinsic discount | PE 21.4x | E 26.0% | ₩73,105.26 | ||
FBIO Fortress Biotech -0.6%7D 43.3%3M | US$3.34 51.1% undervalued intrinsic discount | PE 0.9x | E -106.2% | US$11.00 | ||
ZTS Zoetis -1.6%7D -35.5%3M | US$75.35 13.2% undervalued intrinsic discount | PE 11.8x | E 5.2% | US$113.82 | ||
PRTC PureTech Health -1.6%7D 0.3%3M | UK£1.23 62.8% undervalued intrinsic discount | PB 1.3x | E 20.9% | UK£3.61 | ||
INMD InMode -1.9%7D 5.3%3M | US$15.17 30.1% undervalued intrinsic discount | PE 10x | E -0.7% | US$15.33 | ||
A053030 BINEX -2.1%7D -43.0%3M | ₩6,600.00 70.8% undervalued intrinsic discount | PS 1.3x | S 14.9% | ₩12,550.00 | ||
TDOC Teladoc Health -7.0%7D 52.5%3M | US$8.77 41.5% undervalued intrinsic discount | PS 0.6x | E 35.3% | US$7.97 | ||
RCKT Rocket Pharmaceuticals -7.3%7D -9.4%3M | US$3.19 68.1% undervalued intrinsic discount | PB 1.5x | E 30.7% | US$9.39 | ||
RARE Ultragenyx Pharmaceutical -8.1%7D 11.6%3M | US$26.90 3.5% overvalued intrinsic discount | PS 3.9x | E 71.5% | US$53.37 | ||
AKBA Akebia Therapeutics -9.0%7D -14.7%3M | US$1.22 98.4% undervalued intrinsic discount | PS 1.4x | E 20.3% | US$4.20 | ||
MBIO Mustang Bio -10.5%7D -25.5%3M | US$0.56 68.8% undervalued intrinsic discount | PB 0.5x | S n/a | n/a | ||
ZVRA Zevra Therapeutics -25.4%7D -5.5%3M | US$9.53 36.5% undervalued intrinsic discount | PE 4.8x | E 16.2% | US$26.33 |